Broad Institute of MIT and Harvard/ Dana-Farber Cancer Institute, Boston, MA
Stephanie Anne Mullane , Michael Dunphy , Elana Anastasio , Tania Simoncelli , Kristen Zarrelli , Anthony Philippakis , Rana R. McKay , Toni K. Choueiri , Todd Golub , Eric Lander , Nikhil Wagle , Eliezer Mendel Van Allen , Corrie Painter
Background: While there has been substantial advancement in the genomic understanding of metastatic prostate cancer (MPC), there is still much to be discovered. Additional progress is dependent upon obtaining a large amount of clinically-annotated genomic data. Therefore, we piloted a direct-to-patient nationwide research initiative where patients can contribute their medical records and biospecimens to accelerate research (mpcproject.org). Methods: In collaboration with patients and advocacy groups, we have developed a website (mpcproject.org). Participants are asked to complete a 17-question survey about their experiences with prostate cancer and an electronic informed consent. All participants receive a saliva kit for germline DNA and blood kit for circulating tumor DNA (ctDNA). Additionally, medical records are collected and archived tissue samples are requested if available. Ultra low pass whole genome sequencing (ULP-WGS) and whole exome sequencing (WES) are performed on the whole blood samples. WES is performed on saliva samples. Genomic, clinical, and patient-reported data will be shared widely with the research community. Aggregate study results will be reported to patients. Results: As of October 2017, 12 pilot patients aged 47-74 from 7 states, provided informed consent. 7 saliva kits, 4 blood kits, and 2 medical records were received. 4 patients were diagnosed with de novo metastatic disease, 8 reported a family history of breast and/or prostate cancer, 6 reported a secondary malignancy. All blood kits were submitted for ULP-WGS and WES. Updated genomic, clinical, and patient-reported data will be presented. Conclusions: We have provided preliminary evidence that partnering directly with MPC patients enabled the remote collection of saliva and blood samples, medical records, and patient-reported data. At the conclusion of the pilot phase, the MPC Project will open enrollment for all men with metastatic and advanced prostate cancer in the US and Canada.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Albert Grinshpun
2022 ASCO Genitourinary Cancers Symposium
First Author: Amado J. Zurita
2024 ASCO Genitourinary Cancers Symposium
First Author: Robert Bruce Montgomery
2023 ASCO Annual Meeting
First Author: JJ Haijing Zhang